MedTrace Logo

Insulin Glargine Versus Twice-Daily NPH

NCT00687453 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-11-02

Study results available
· View outcomes & findings →

Summary

To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.

Conditions

Interventions

DRUG

Insulin glargine at bedtime instead of NPH

Insulin glargine at bedtime substituting for NPH insulin at bedtime

DRUG

NPH twice-daily

Addition of morning NPH to bedtime NPH

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Charles Drew University of Medicine and Science

    lead OTHER

Principal Investigators

  • Stanley Hsia, MD · Charles Drew University of Medicine and Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687453 on ClinicalTrials.gov